Here's Why You Should Retain IQV Stock in Your Portfolio Now
IQVIA Holdings shares jump 25.5% in three months as AWS partnership, growing R&DS backlog and buybacks lift its earnings outlook.
IQVIA: Increasingly Indispensable In Drug Development
IQVIA Holdings is positioned as the indispensable data and technology backbone of the life sciences industry, far beyond a traditional CRO. Long-term revenue visibility is underpinned by a record $32.4B backlog, technology-driven margin expansion, and robust buyback-enhanced EPS growth. IQV's unique, comprehensive data assets and AI-enabled services create a defensible moat, insulating it from both Big Tech and CRO competition.
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is IQVIA (IQV) Up 6.4% Since Last Earnings Report?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
IQVIA Holdings Inc. (IQV) Presents at UBS Global Healthcare Conference 2025 Transcript
IQVIA Holdings Inc. ( IQV ) UBS Global Healthcare Conference 2025 November 11, 2025 12:30 PM EST Company Participants Ari Bousbib - CEO & Chairman Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Presentation Daniel Leonard UBS Investment Bank, Research Division All right. We're live.
IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
IQVIA (IQV) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for IQVIA (IQV) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
IQVIA Earnings & Revenues Beat Estimates in Q3, Increase Y/Y
IQV posts stronger-than-expected third-quarter 2025 earnings and revenue gains. It lifts the full-year guidance as all key segments show growth momentum.
IQVIA Holdings Inc. (IQV) Q3 2025 Earnings Call Transcript
IQVIA Holdings Inc. (NYSE:IQV ) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Kerri Joseph - SVP of Investment Relation & Treasury Ari Bousbib - CEO & Chairman Ronald Bruehlman - Executive VP & CFO Michael Fedock - Senior Vice President of Financial Planning and Analysis Conference Call Participants David Windley - Jefferies LLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Michael Cherny - Leerink Partners LLC, Research Division Shlomo Rosenbaum - Stifel, Nicolaus & Company, Incorporated, Research Division Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Jeffrey Garro - Stephens Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by.
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IQVIA (IQV) Reliance on International Sales: What Investors Need to Know
Explore IQVIA's (IQV) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
IQVIA: Q2 Earnings Exceeded My Expectations
IQVIA Holdings Inc.'s Q1 results highlighted strong profitability, robust TAS growth, and a healthy backlog, reaffirming its leadership in healthcare data and analytics. Despite sector headwinds, I remained bullish on IQVIA and expected Q2 to meet or beat estimates, viewing analyst forecasts as a conservative floor. The company did not disappoint. Key risks include delayed clinical trials, shrinking CSMS segment, regulatory challenges, and high debt, but these do not shake my conviction.
